semaglutide heart failure Impact of 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With in the United States (SHINE-HF) FDA Clears Semaglutide For Cardiac

Oral agents may be preferable for individuals who are hesitant to initiate injectable therapies, or for health systems where refrigeration and cold-chain logistics pose barriers

Your healthcare provider may need to adjust your dose , slow the titration schedule, or consider alternative medications if side effects remain intolerable despite conservative management

There are also oversight concerns

FDA has evaluated the following bulk drug substances and determined that there is a clinical need for outsourcing facilities to compound drug products using these bulk drug substances under section 503B of the FD&C Act: One key condition: Facility generally cannot compound drugs using bulk drug substances unless that substance appears on the FDA's '503B Bulks List' (substances for which there is a demonstrated clinical need) or the compounded drug is on the FDA's active drug shortage list